LivaNova (NASDAQ:LIVN) Stock Rating Upgraded by Wall Street Zen

LivaNova (NASDAQ:LIVN) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.

Several other brokerages have also commented on LIVN. Robert W. Baird set a $75.00 price target on LivaNova in a research note on Tuesday. Needham & Company LLC restated a “buy” rating and issued a $64.00 target price on shares of LivaNova in a research note on Wednesday, September 3rd. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of LivaNova in a report on Monday. KeyCorp began coverage on shares of LivaNova in a report on Friday. They set an “overweight” rating and a $81.00 price target for the company. Finally, Mizuho boosted their price target on shares of LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $65.63.

LivaNova Stock Up 1.2%

NASDAQ LIVN opened at $62.82 on Friday. LivaNova has a 1-year low of $32.48 and a 1-year high of $65.57. The company has a market capitalization of $3.43 billion, a price-to-earnings ratio of -15.70 and a beta of 1.02. The stock’s 50 day moving average is $57.31 and its two-hundred day moving average is $52.21. The company has a current ratio of 1.33, a quick ratio of 1.12 and a debt-to-equity ratio of 0.30.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tudor Investment Corp ET AL acquired a new stake in LivaNova in the 3rd quarter valued at about $1,746,000. CIBC Bancorp USA Inc. bought a new stake in shares of LivaNova during the third quarter valued at approximately $304,000. Oberweis Asset Management Inc. acquired a new stake in shares of LivaNova in the third quarter valued at approximately $9,743,000. Shelton Capital Management bought a new position in LivaNova in the 3rd quarter worth approximately $325,000. Finally, Quarry LP bought a new position in LivaNova in the 3rd quarter worth approximately $36,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.